The Goldman Sachs Group Forecasts Strong Price Appreciation for Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective lifted by The Goldman Sachs Group from $75.00 to $90.00 in a research report issued on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. The Goldman Sachs Group’s price objective indicates a potential upside of 14.26% from the company’s previous close.

A number of other equities research analysts have also recently commented on KNSA. Canaccord Genuity Group raised their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the company a “buy” rating in a research note on Wednesday. Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, July 12th. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $99.00 and gave the company an “outperform” rating in a research note on Wednesday. Wells Fargo & Company boosted their target price on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the stock an “overweight” rating in a research report on Monday, July 13th. Finally, Citigroup raised their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $87.38.

Kiniksa Pharmaceuticals International Price Performance

Shares of NASDAQ:KNSA traded down $2.15 during mid-day trading on Thursday, hitting $78.77. The company had a trading volume of 562,634 shares, compared to its average volume of 732,357. Kiniksa Pharmaceuticals International has a one year low of $29.90 and a one year high of $82.94. The firm has a fifty day moving average price of $58.13 and a 200 day moving average price of $50.71. The company has a market capitalization of $6.06 billion, a PE ratio of 81.21 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 earnings per share for the quarter, meeting the consensus estimate of $0.30. The firm had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 14.16%. Research analysts expect that Kiniksa Pharmaceuticals International will post 1.25 earnings per share for the current fiscal year.

Insider Activity

In other Kiniksa Pharmaceuticals International news, CEO Sanj K. Patel sold 48,565 shares of the stock in a transaction dated Friday, May 1st. The shares were sold at an average price of $54.02, for a total value of $2,623,481.30. Following the completion of the sale, the chief executive officer owned 48,565 shares in the company, valued at approximately $2,623,481.30. This trade represents a 50.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the transaction, the insider directly owned 65,623 shares of the company’s stock, valued at approximately $3,524,611.33. This represents a 47.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 51.98% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Large investors have recently added to or reduced their stakes in the stock. Rubric Capital Management LP grew its position in shares of Kiniksa Pharmaceuticals International by 2.3% during the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock valued at $155,320,000 after acquiring an additional 90,194 shares during the period. Vanguard Group Inc. increased its position in Kiniksa Pharmaceuticals International by 1.6% in the fourth quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock worth $128,409,000 after buying an additional 49,802 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in shares of Kiniksa Pharmaceuticals International by 45.3% in the third quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock valued at $41,481,000 after buying an additional 332,846 shares during the period. Qube Research & Technologies Ltd grew its stake in shares of Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock worth $24,581,000 after acquiring an additional 653,236 shares during the period. Finally, Millennium Management LLC increased its holdings in Kiniksa Pharmaceuticals International by 8.7% in the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock worth $18,815,000 after acquiring an additional 67,452 shares during the last quarter. Hedge funds and other institutional investors own 53.95% of the company’s stock.

Key Kiniksa Pharmaceuticals International News

Here are the key news stories impacting Kiniksa Pharmaceuticals International this week:

• Positive Sentiment: Kiniksa raised its 2026 revenue guidance and highlighted progress in its development pipeline, driving a substantial prior-session rally. The company’s quarterly results also included adjusted earnings of $0.30 per share, in line with estimates, while revenue of $243.6 million exceeded consensus expectations of $226.5 million. Why Kiniksa Pharmaceuticals Is Up After Raising Guidance
• Positive Sentiment: Several analysts raised their price targets following the guidance update: JPMorgan increased its target to $107 and maintained an overweight rating; Canaccord Genuity raised its target to $98 with a buy rating; Wedbush lifted its target to $99 with an outperform rating; and Citi raised its target to $100 with a buy rating. These targets imply further upside from recent levels. Analyst Price Target Changes
• Positive Sentiment: Rising earnings estimates could support continued momentum, as improving forecasts often attract additional investor interest. Earnings Estimates Rising for Kiniksa
• Neutral Sentiment: The company scheduled its second-quarter 2026 financial results announcement for July 28, providing the latest earnings and guidance update for investors. Kiniksa Q2 2026 Results Announcement
• Negative Sentiment: Valuation is becoming a concern after the rally. One analysis estimates KNSA could be approximately 16% overvalued even after the company raised its 2026 outlook, which may be encouraging profit-taking and limiting gains. Could Kiniksa Be Overvalued

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.